Developing medicines is a minefield that Tranzyme Pharma has navigated well so far. But the Durham company is about to embark on one of its trickiest missions.
Posts Tagged ‘pharma’
RTP Wrapup 2/5
Friday, February 5, 2010, 12:13 amGlaxoSmithKline wants to scale back research and development and the cuts could affect jobs at the British drugmaker’s U.S. headquarters in Research Triangle Park, IBM unveils the $360 million cloud computing center it established on its RTP campus and a Durham startup reels in $10.5 million in venture capital and a deal with Burlington-based medical testing giant LabCorp. Read more…
Genes as weather vanes for disease
Monday, November 2, 2009, 2:33 pmImagine a chemist, a bioethicist, a pharmacist and a physician come together to discuss personalized medicine. The last thing you expect them to talk about is the need to wear matching jackets like TV weather forecasters.
But that’s exactly what a panel of experts did Monday at the RTI Fellows Symposium at the University of North Carolina’s Friday Center in Chapel Hill.
RTP Wrapup 9/25
Thursday, September 24, 2009, 4:48 pmMicell Technologies receives $15 million from St. Jude Medical, GlaxoSmithKline curbs its funding educational programs that bring doctors up-to-date, Duke Genome Center gets a $19.5 million grant and a consortium of area universities and nonprofit organizations are chasing a piece of the $63 billion the Obama Administration wants to spend over the next six years on global health care programs.
RTP Wrapup 9/18
Thursday, September 17, 2009, 7:13 pmSalix Pharmaceuticals watches its stock soar and Pozen takes action to broaden the scope of the company while GlaxoSmithKline waits for regulatory approval of two vaccines.
Salix soars on rifaximin data
Wednesday, September 16, 2009, 5:11 amSalix Pharmaceuticals, a Morrisville company that specializes in gastrointestinal treatments, has seen its shares rise nearly 50 percent in the past two days.
Investors rushed to trade the stock after Salix announced results from two late-stage studies Monday that showed rifaximin works better than placebo in treating non-constipation irritable bowel syndrome. Salix sells rifaximin for traveler’s diarrhea under the name Xifaxan.
RTP Wrapup 9/4
Thursday, September 3, 2009, 6:23 pmA report offers hope that federal funds could become available for economic development in innovation hot spots such as the Research Triangle area, Bayer CropScience adds a research collaboration to recent efforts of creating better biotech seeds and Family Health International, a Durham organization that aims to improve public health worldwide, uses realty shows to stem the spread of HIV/AIDS.
Next: A crucial decision
Thursday, September 3, 2009, 8:23 amThis is the last part. Continued from part 2.
Getting a ghrelin drug to market
Thursday, September 3, 2009, 8:20 amThis is the second part of three. Continued from part 1.
Work on promising ghrelin medicines has gotten to a critical stage a decade after Japanese researchers discovered the hormone that stimulates hunger and is linked to insulin production.
Ghrelin: A new hormone is found
Thursday, September 3, 2009, 8:15 amINTRODUCTION
Tranzyme Pharma is one of dozens of drug development companies in North Carolina’s Research Triangle area, a biotech hot spot that is ranked third in the nation by number of companies. The Durham company has diligently advanced therapies based on a hormone that was discovered a decade ago, a technology also used by two rivals. Now, Tranzyme’s Board of Directors has to decide how to pay for the final development step and get its drugs to market: Go public, sell the company or go back to its investors hat in hand one more time.
This is the first part of three.
Icagen doing better
Tuesday, August 4, 2009, 4:45 amAfter months of wrangling with an influential investor — the argument included calls for the resignation of the chief executive — things are looking up again at Icagen, a Durham company working on painkillers and asthma and epilepsy treatments.
At least for the moment they are.
